Media stories about Vericel Corporation (NASDAQ:VCEL) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vericel Corporation earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.6369843248832 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of analysts have weighed in on VCEL shares. BTIG Research started coverage on Vericel Corporation in a research note on Tuesday, June 20th. They issued a “buy” rating and a $6.00 target price on the stock. Piper Jaffray Companies reiterated a “buy” rating and issued a $7.00 target price on shares of Vericel Corporation in a research note on Thursday, August 10th.
Vericel Corporation (VCEL) traded down 0.0023% during mid-day trading on Wednesday, reaching $4.2999. The company’s stock had a trading volume of 9,803 shares. Vericel Corporation has a 12-month low of $2.00 and a 12-month high of $4.70. The stock’s market cap is $141.14 million. The firm’s 50 day moving average price is $3.60 and its 200 day moving average price is $3.04.
Vericel Corporation (NASDAQ:VCEL) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.16. The business had revenue of $16.95 million during the quarter. On average, equities analysts predict that Vericel Corporation will post ($0.63) earnings per share for the current year.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.